Drug name - Tukysa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(2 years from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases May, 2027

(4 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor Oct, 2032

(10 years from now)

Drugs and Companies using TUCATINIB ingredient

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription